Orgenesis Stock (NASDAQ:ORGS)


RevenueOwnershipFinancialsChart

Previous Close

$4.42

52W Range

$2.50 - $10.80

50D Avg

$6.56

200D Avg

$5.70

Market Cap

$20.85M

Avg Vol (3M)

$22.58K

Beta

1.21

Div Yield

-

ORGS Company Profile


Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

146

IPO Date

Mar 13, 2012

Website

ORGS Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Eliminations$-4.42M$-5.58M-
Consolidated-$1.28M-
POC and Hospital Services--$32.82M
Cell Process Development Services--$2.68M

Fiscal year ends in Dec 23 | Currency in USD

ORGS Financial Summary


Dec 23Dec 22Dec 21
Revenue$530.00K$36.02M$35.50M
Operating Income$-51.48M$-7.37M$-42.68M
Net Income$55.36M$-12.17M$-18.06M
EBITDA$-51.48M$-6.90M$-13.85M
Basic EPS-$-0.48$-0.74
Diluted EPS-$-0.48$-0.74

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q1 23Aug 11, 23 | 12:00 AM
Q4 22Mar 21, 23 | 4:08 PM
Q3 22Nov 13, 22 | 9:29 PM

Peer Comparison


TickerCompany
TALSTourmaline Bio, Inc.
ONCROncorus, Inc.
ACHLAchilles Therapeutics plc
LIXTLixte Biotechnology Holdings, Inc.
KTTAPasithea Therapeutics Corp.
AVTEAerovate Therapeutics, Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
QNRXQuoin Pharmaceuticals, Ltd.
ANTXAN2 Therapeutics, Inc.
DSGNDesign Therapeutics, Inc.
RZLTRezolute, Inc.
TFFPTFF Pharmaceuticals, Inc.
INDPIndaptus Therapeutics, Inc.
NRBONeuroBo Pharmaceuticals, Inc.
ADAGAdagene Inc.
TNGXTango Therapeutics, Inc.
ELYMEliem Therapeutics, Inc.